Novel maxi-k channel blockers, methods of use and process for making the same
OwnerMichael Goetz, Gregory Kaczorowski +3inventors
InventorsMichael Goetz, Gregory Kaczorowski, Richard Monaghan, William Strohl, Jan Tkacz
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
Claims11
A method for treating ocular hypertension or glaucoma which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Table 1:
- TABLE 1
- PC-M4
- PC-M5
- pennigritrem
- Secopenitrem B
- Sulpinine A
- Sulpinine B
- Lolitrem N
- Lolitrem N, 31-epimer
- penitrem F
- penitrem B
- 10-oxo, 11,33-dihydro, 15-deoxy, dechloro penitrem A
- penitrem C
- penitrem D
- penitrem E
- 6-bromo-penitrem D
- Loilline
- Lolitriol
- Lolicine A
- Lolicine B
- emindole DA
- epi-emindole DA
- emindole PA
- emindole DB
- emindole SB
- terpendole A
- terpendole B
- terpendole C
- terpendole D
- Terpendole E
- Terpendole G
- Terpendole F
- Terpendole H
- Terpendole I
- Terpendole J
- Terpendole K
- Terpendole L
- Terpendole M
- verruculogen
- 8-acetoxy-verruculogen
- nominine
- paspalicine
- paspaline
- paspaline B
- paspalinine
- Paspalitrem A
- Paspalitrem B
- Paspalitrem C
- Fumitremorgen A
- Janthitrem B
- Janthitrem C
- Janthitrem E
- Janthitrem F
- Janthitrem G
- Lolitrem A
- Lolitrem B
- Lolitrem C
- Lolitrem E
- Lolitrem F
- Lolitrem H
- shearinine A
- shearinine B
- shearinine B isomer
- shearinine C
- Shearinine C, 1′-deoxy, 1′,2′-didehydRo,3-beta alcohol
- paxilline
- paxilline, 14-hydroxy
- paxilline, 14-hydroxy, 4b-deoxy
- paxilline, 1-acetyl
- paxilline, 3-acetyl
- 4b-deoxypaxilline
- 4b-deoxypaxilline, 3-acetyl
- 9-prenylpaxilline
- or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer or mixture thereof.
The method according to claim 3 wherein the topical formulation is a solution or suspension.
Dependencies are inferred from the claim text.